Maria Schwaederle

TL;DR: Targeting of a larger fraction of identified molecular alterations, yielding a higher ‘matching score’, was correlated with significantly improved disease control rates, as well as longer progression-free and overall survival rates, compared to targeting of fewer somatic alterations.

TL;DR: Comprehensive analysis of phase II, single-agent arms revealed that, across malignancies, a personalized strategy was an independent predictor of better outcomes and fewer toxic deaths.

TL;DR: Over-expressed HER2 was detected predominantly in malignancies of epithelial origin; for cancers derived from mesenchyme, neuroendocrine tissue, central nervous system, and kidney, HER2 expression and amplification were remarkably rare or non-existent.

TL;DR: Using a biomarker-based approach to cancer treatment strategy was associated with significantly improved outcomes (RR and PFS) and response rates were significantly higher with genomic vs protein biomarkers.

TL;DR: Genomic sequencing is revealing complex molecular profiles that differ by patient, which may help optimize management and barriers to personalized therapy include access to appropriately targeted drugs.